Clinical Trial Update: Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the effect of a prostacyclin (PGI2) analogue on the development of chronic allograft nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allograft Nephropathy

Drugs mentioned

• PGI2 analogue (prostacyclin analogue)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Chronic Allograft Nephropathy | Phase 3 | Status: COMPLETED